A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : SPMs / specialized pro-resolving mediators

[Related PubMed/MEDLINE]
Total Number of Papers: 112
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   SPMs  (>> Co-occurring Abbreviation)
Long Form:   specialized pro-resolving mediators
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Can Inflammation-Resolution Provide Clues to Treat Patients According to Their Plaque Phenotype? ---
2019 Development of an Optimized LC-MS Method for the Detection of Specialized Pro-Resolving Mediators in Biological Samples. ARA, DHA, EMA, EPA, n-3 PUFA
2019 Eicosanoid and Specialized Proresolving Mediator Regulation of Lymphoid Cells. LMs, LTB4, PGE2
2019 Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial). PAD, PUFA
2019 Frontline Science: Specialized proresolving lipid mediators inhibit the priming and activation of the macrophage NLRP3 inflammasome. CARD, NLRP3, RvD2
2019 Leukocytes from obese individuals exhibit an impaired SPM signature. DHAs, HDHA, LOX, Rvs
2019 Neuroinflammation in hypertension: the renin-angiotensin system versus pro-resolution pathways. omega-3 PUFAs
2019 Non-type 2 inflammation in severe asthma is propelled by neutrophil cytoplasts and maintained by defective resolution. ---
2019 Plasma oxylipins respond in a linear dose-response manner with increased intake of EPA and DHA: results from a randomized controlled trial in healthy humans. DHA, EPA, n-3 PUFAs
10  2019 Pro-resolving lipid mediators in the resolution of neointimal hyperplasia pathogenesis in atherosclerotic diseases. NIH, vSMCs
11  2019 Resolution of inflammation in neuromyelitis optica spectrum disorders. ANXA1, AQP4, CBA, CSF, LTB4, NMOSD, RvD1
12  2019 Resolvin D2 elevates cAMP to increase intracellular [Ca2+] and stimulate secretion from conjunctival goblet cells. 8-Br-cAMP, CGCs, Rvs
13  2019 Roles, Actions, and Therapeutic Potential of Specialized Pro-resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis. CF
14  2019 Saving Problematic Mucosae: SPMs in Intestinal Mucosal Inflammation and Repair. IBD
15  2018 15-epi-Lipoxin A4, Resolvin D2, and Resolvin D3 Induce NF-kappaB Regulators in Bacterial Pneumonia. SIGIRR
16  2018 Accelerating the reversal of inflammatory pain with NPD1 and its receptor GPR37. ---
17  2018 AT-RVD1 repairs mouse lung after cigarette smoke-induced emphysema via downregulation of oxidative stress by NRF2/KEAP1 pathway. CS
18  2018 Can inflammation be resolved in Alzheimer's disease? AD
19  2018 Can Specialized Pro-resolving Mediators Deliver Benefit Originally Expected from Fish Oil? ARDS, FO, PICS, RCTs
20  2018 Combined administration of resolvin E1 and lipoxin A4 resolves inflammation in a murine model of Alzheimer's disease. AD, LXA4, RvE1
21  2018 Distinct Analgesic Actions of DHA and DHA-Derived Specialized Pro-Resolving Mediators on Post-operative Pain After Bone Fracture in Mice. DHA, i.t, NPD1
22  2018 Frontline Science: A reduction in DHA-derived mediators in male obesity contributes toward defects in select B cell subsets and circulating antibody. 14-HDHA, 17-HDHA, DHA, PDX
23  2018 Function of Pro-Resolving Lipid Mediator Resolvin E1 in Type 2 Diabetes. RvE1, T2D
24  2018 Host Lipid Mediators in Leprosy: The Hypothesized Contributions to Pathogenesis. PUFAs
25  2018 Identification of proresolving and inflammatory lipid mediators in human psoriasis. LMs, PsO, Rvs
26  2018 Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation. DHA, EPA, LM, LPS, LX, PUFA, Rv
27  2018 Immunoregulatory role of 15-lipoxygenase in the pathogenesis of bacterial keratitis. LOX
28  2018 Immunotherapy of Mild Cognitive Impairment by omega-3 Supplementation: Why Are Amyloid-beta Antibodies and omega-3 Not Working in Clinical Trials? AD, MCI
29  2018 Key roles for lipid mediators in the adaptive immune response. ---
30  2018 Maresins: Specialized Proresolving Lipid Mediators and Their Potential Role in Inflammatory-Related Diseases. DHA
31  2018 MerTK signaling in macrophages promotes the synthesis of inflammation resolution mediators by suppressing CaMKII activity. CaMKII, LOX, MAPK, SERCA2
32  2018 Metabololipidomic profiling of functional immunoresolvent clusters and eicosanoids in mammalian tissues. LM, RvE1, WB
33  2018 Neuronal SphK1 acetylates COX2 and contributes to pathogenesis in a model of Alzheimer's Disease. AD, COX2, SphK1
34  2018 New perspectives in cancer: Modulation of lipid metabolism and inflammation resolution. PUFA
35  2018 Pro-resolving lipid mediators in vascular disease. ---
36  2018 Pro-resolving lipid mediators: Agents of anti-ageing? ---
37  2018 Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli-driven acute inflammation. ---
38  2018 Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. ---
39  2018 Roles of Specialized Pro-Resolving Lipid Mediators in Cerebral Ischemia Reperfusion Injury. ---
40  2018 Signaling pathways activated by resolvin E1 to stimulate mucin secretion and increase intracellular Ca2+ in cultured rat conjunctival goblet cells. RvE1
41  2018 Specialized pro-resolving lipid mediators in experimental periodontitis: A systematic review. PRISMA, SYRCLE
42  2018 Specialized Pro-Resolving Lipid Mediators Regulate Ozone-Induced Pulmonary and Systemic Inflammation. BAL, FA
43  2018 Specialized Pro-resolving Mediators Regulate Alveolar Fluid Clearance during Acute Respiratory Distress Syndrome. AFC, ARDS, CFTR
44  2018 Specialized Proresolving Mediators in Innate and Adaptive Immune Responses in Airway Diseases. ---
45  2018 Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution. LXs, MaRs, NASH, Rvs
46  2018 Splenic leukocytes define the resolution of inflammation in heart failure. ---
47  2018 Structural insights into Resolvin D4 actions and further metabolites via a new total organic synthesis and validation. ---
48  2018 Targeting lipid mediators in cancer biology. ---
49  2018 The role of non-resolving inflammation in atherosclerosis. ---
50  2018 The roles of special proresolving mediators in pain relief. ---
51  2017 A cluster of immunoresolvents links coagulation to innate host defense in human blood. LMs, RvE1, WB
52  2017 Annexin A1 and specialized proresolving lipid mediators: promoting resolution as a therapeutic strategy in human inflammatory diseases. ANXA1
53  2017 B Cell Activity Is Impaired in Human and Mouse Obesity and Is Responsive to an Essential Fatty Acid upon Murine Influenza Infection. DHA
54  2017 Biosynthesis of proresolving lipid mediators by vascular cells and tissues. 17-HDHA, DHA, ECs, LOX, RvD1, VSMCs
55  2017 Bronchoprotective mechanisms for specialized pro-resolving mediators in the resolution of lung inflammation. CF, COPD
56  2017 Comparative effects of the omega3 polyunsaturated fatty acid derivatives resolvins E1 and D1 and protectin DX in models of inflammation and pain. PDX, Rvs
57  2017 Corticosteroids inhibit anti-IgE activities of specialized proresolving mediators on B cells from asthma patients. ---
58  2017 Effects of postnatal omega-3 fatty acid supplementation on offspring pro-resolving mediators of inflammation at 6 months and 5 years of age: A double blind, randomized controlled clinical trial. DHA, EPA
59  2017 Fine-tuning inflammation-resolution programs: focus on atherosclerosis. ---
60  2017 Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways. FPR1, GC, LXB4, PUFA, RvD1
61  2017 Maresin 1 improves insulin sensitivity and attenuates adipose tissue inflammation in ob/ob and diet-induced obese mice. DIO, MaR1, WAT
62  2017 Maresin 1 induces a novel pro-resolving phenotype in human platelets. ---
63  2017 Omega-3 Polyunsaturated Fatty Acids in Critical Illness: Anti-Inflammatory, Proresolving, or Both? DHA, EPA, PUFAs
64  2017 Plasma lipoxin A4 and resolvin D1 are not associated with reduced adenoma risk in a randomized trial of aspirin to prevent colon adenomas. LXA4, RvD1
65  2017 Pro-resolution therapeutics for cardiovascular diseases. LTB4
66  2017 Pro-resolving lipid mediator Resolvin D1 serves as a marker of lung disease in cystic fibrosis. AA, CF, CFTR, DHA, LXs, MaRs, RvD1, Rvs
67  2017 Resolving inflammation by using nutrition therapy: roles for specialized proresolving mediators. ---
68  2017 Special pro-resolving mediator (SPM) actions in regulating gastro-intestinal inflammation and gut mucosal immune responses. SPM
69  2017 Specialized pro-resolving mediators in cardiovascular diseases. ---
70  2017 Specialized pro-resolving mediators in renal fibrosis. ---
71  2017 The expansive role of oxylipins on platelet biology. COXs, CYP450, LOXs, PUFAs
72  2017 Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. ---
73  2016 A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease. CKD, CVD, DHA, EPA
74  2016 DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation. ---
75  2016 Divergent shifts in lipid mediator profile following supplementation with n-3 docosapentaenoic acid and eicosapentaenoic acid. DHA, DPA, EPA, LC, MaR, PUFA, RvD5n-3DPA, RvE
76  2016 Docosapentaenoic acid derived metabolites and mediators - The new world of lipid mediator medicine in a nutshell. AA, DHA, EPA
77  2016 MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation. ADAM17, I/R, MerTK
78  2016 n-3 Fatty acid supplementation and proresolving mediators of inflammation. ---
79  2016 Novel Endogenous Proresolving Molecules:Essential Fatty Acid-Derived and Gaseous Mediators in the Resolution of Inflammation. CO, HO, LMs
80  2016 Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Abeta42 Phagocytosis. AD, ENT, LC-MS-MS, LMs, LXA4, MaR1, PD1, PDX, PGD2, Rv, RvD1
81  2016 Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses. DHA, Th1, Treg
82  2016 Resolvin D1 Dampens Pulmonary Inflammation and Promotes Clearance of Nontypeable Haemophilus influenzae. AT-RvD1, NTHi
83  2016 Resolvin D2 decreases TLR4 expression to mediate resolution in human monocytes. RvD2
84  2016 Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation. Rvs
85  2016 Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. ---
86  2016 Specialized proresolving mediators (SPMs) inhibit human B-cell IgE production. 17-HDHA, RvD1
87  2016 Stretching Impacts Inflammation Resolution in Connective Tissue. ---
88  2016 The neuroimmune guidance cue netrin-1 controls resolution programs and promotes liver regeneration. I/R, PMNs
89  2015 Bioactive products formed in humans from fish oils. EETs, iPs, LPS
90  2015 Determination of omega-6 and omega-3 PUFA metabolites in human urine samples using UPLC/MS/MS. AA, DHA, EPA, PUFAs, Rvs
91  2015 Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. AD, PBMCs
92  2015 Insufficient resolution response in the hippocampus of a senescence-accelerated mouse model--SAMP8. AD, L12-LOX, SAMP8, SAMR1
93  2015 Maresin 1 Biosynthesis and Proresolving Anti-infective Functions with Human-Localized Aggressive Periodontitis Leukocytes. 14-HDHA, HC, LAP, MaR1
94  2015 Resolution of inflammation is altered in Alzheimer's disease. AD, CSF, LXA4, MMSE
95  2015 Resolvins AT-D1 and E1 differentially impact functional outcome, post-traumatic sleep, and microglial activation following diffuse brain injury in the mouse. mFPI, NOR, TBI
96  2015 Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages. COPD
97  2015 Specialized Pro-Resolving Mediators from Omega-3 Fatty Acids Improve Amyloid-beta Phagocytosis and Regulate Inflammation in Patients with Minor Cognitive Impairment. AD, MCI, PBMCs
98  2015 Specialized proresolving lipid mediators in humans with the metabolic syndrome after n-3 fatty acids and aspirin. 14-HDHA, 17-HDHA, 18-HEPE, MetS
99  2015 Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice. DHA, MaR1, RvD2
100  2015 The Regulation of Proresolving Lipid Mediator Profiles in Baboon Pneumonia by Inhaled Carbon Monoxide. CO, LM, RvE